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IMPORTANCE Chronic obstructive pulmonary disease (COPD) is a major global health issue
and theophylline is used extensively. Preclinical investigations have demonstrated that low
plasma concentrations (1-5 mg/L) of theophylline enhance antiinflammatory effects of
corticosteroids in COPD.
OBJECTIVE To investigate the effectiveness of adding low-dose theophylline to inhaled
corticosteroids in COPD.
DESIGN, SETTING, AND PARTICIPANTS The TWICS (theophyllinewith inhaled corticosteroids)
trial was a pragmatic, double-blind, placebo-controlled, randomized clinical trial that enrolled
patients with COPDbetween February 6, 2014, and August 31, 2016. Final follow-up ended on
August 31, 2017. Participants had a ratio of forced expiratory volume in the first second to forced
vital capacity (FEV1/FVC) of less than 0.7with at least 2 exacerbations (treatedwith antibiotics,
oral corticosteroids, or both) in the previous year andwere using an inhaled corticosteroid. This
study included 1578 participants in 121 UK primary and secondary care sites.
INTERVENTIONS Participants were randomized to receive low-dose theophylline (200mg
once or twice per day) to provide plasma concentrations of 1 to 5mg/L (determined by ideal
body weight and smoking status) (n = 791) or placebo (n = 787).
MAIN OUTCOMES ANDMEASURES The number of participant-reportedmoderate or severe
exacerbations treated with antibiotics, oral corticosteroids, or both over the 1-year
treatment period.
RESULTS Of the 1567 participants analyzed, mean (SD) age was 68.4 (8.4) years and 54%
(843) were men. Data for evaluation of the primary outcomewere available for 1536
participants (98%) (772 in the theophylline group; 764 in the placebo group). In total, there
were 3430 exacerbations: 1727 in the theophylline group (mean, 2.24 [95% CI, 2.10-2.38]
exacerbations per year) vs 1703 in the placebo group (mean, 2.23 [95% CI, 2.09-2.37]
exacerbations per year); unadjustedmean difference, 0.01 (95% CI, −0.19 to 0.21) and
adjusted incidence rate ratio, 0.99 (95% CI, 0.91-1.08). Serious adverse events in the
theophylline and placebo groups included cardiac, 2.4% vs 3.4%; gastrointestinal, 2.7% vs
1.3%; and adverse reactions such as nausea (10.9% vs 7.9%) and headaches (9.0% vs 7.9%).
CONCLUSIONS AND RELEVANCE Among adults with COPD at high risk of exacerbation treated
with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo,
did not reduce the number COPD exacerbations over a 1-year period. The findings do not
support the use of low-dose theophylline as adjunctive therapy to inhaled corticosteroids for
the prevention of COPD exacerbations.
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C hronic obstructive pulmonary disease (COPD) iswell recognized as a major growing global healthconcern.1,2 An important clinical feature of COPD is
acute exacerbations, which are adversely associated with
morbidity3 and mortality4 and are the most costly aspect of
COPD for health care systems.2
Oral theophylline has been used as a bronchodilator to
treat COPD for decades; however, to achieve modest bron-
chodilatation through phosphodiesterase inhibition, blood
concentrations (10-20 mg/L) are required that are associated
with adverse effects.5 Recently there has been interest in
using theophylline at a low dose in COPD to achieve plasma
levels of 1 to 5 mg/L. Preclinical investigations have demon-
strated that at low plasma concentrations (1-5 mg/L), there
is marked synergism between theophylline and corticoste-
roids, with theophylline inducing a 100- to 10 000-fold
increase in antiinflammatory effects of corticosteroids.6-9
Small exploratory clinical studies have reported that low-
dose theophylline increases the antiinflammatory prop-
erties of inhaled corticosteroids (ICS) as evidenced by
biomarkers.10,11 The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) management strategy guideline does
not recommend the use of theophylline unless other
long-term treatment bronchodilators are unavailable or
unaffordable. The issue of affordability and availability are
important determinants of theophylline use globally, and
in resource-limited countries with high burdens of COPD,
theophylline continues to be used extensively.12-15
The GOLD management strategy guideline does not
dismiss the use of low-dose theophylline, highlighting
that the clinical relevance of low-dose theophylline has not
been fully established and that clinical evidence on low-
dose theophylline, particularly on exacerbations, is limited
and contradictory.5 The TWICS (theophylline with inhaled
corticosteroids) trial addressed this area of clinical uncer-
tainty by investigating the clinical effectiveness of adding
low-dose theophylline to inhaled corticosteroid (ICS)
therapy in people with COPD and frequent exacerbations,
with the rate of moderate and severe exacerbations as the
primary outcome.
Methods
This trial was reviewed and approved by ScotlandAResearch
Ethics Committee (13/SS/0081) and the Medicines and
Healthcare products Regulatory Agency (EudraCT 2013-
001490-25). The trial was registered on September 19, 2013,
and theprotocol appears inSupplement 1 andSupplement2.16
All participants provided written informed consent.
Study Design andOversight
A pragmatic, UK-based, multicenter, double-blind, random-
ized clinical trial compared addition of low-dose theophyl-
line or placebo for 52 weeks to current therapy that included
ICS in patients with COPD and at least 2 exacerbations in the
previous year. The trial aimed to recruit 1424 participants
with at least 50% being recruited in primary care.
Participants
Participants were identified and recruited from primary and
secondary (hospital) care sites across the United Kingdom.
In primary care, general practice staff conducted searches of
their patients’ electronic patient records (based on inclusion/
exclusion criteria) to identify potential participants. Potential
participants were also identified from community COPD ser-
vices such as pulmonary rehabilitation departments, COPD
community matrons, smoking cessation services, and
COPD integrated and intermediate care services. Potentially
suitable patients were sent study information packs and con-
tact details to be seen in their local primary care research site
by primary care staff, if interested. In secondary care, poten-
tial participants were identified from patients attending (or
who had previously attended) respiratory outpatient clinics
or who had been inpatients. Potentially suitable patients
were sent study information and contact details to be seen in
their local secondary care research site by secondary care
staff, if interested.
Participants were aged 40 years or older with a predomi-
nant respiratory diagnosis of COPD (ratio of forced expiratory
volume in the first second to forced vital capacity [FEV1/FVC]
of <0.7); a smoking history of more than 10 pack-years; cur-
rent use of ICS; and 2 or more exacerbations treated with an-
tibiotics, oral corticosteroids, or both in thepreviousyear. The
diagnosis of COPDwas established from clinical records dur-
ing screening and spirometry conducted at study recruit-
ment. Smoking and exacerbation history was ascertained by
participant recall. Potential participantswere excluded if they
had a predominant respiratory disease other than COPD, se-
vere or unstable ischemic heart disease, or were using drugs
with thepotential to increaseplasma theophylline concentra-
tion to greater than 1 to 5 mg/L.17
Randomization/Treatment Allocation
Participants were stratified by region and recruitment set-
ting (primary or secondary care) and randomized with equal
probability (1:1) to receive low-dose theophylline or placebo.
The random allocation sequence was generated using ran-
domly generated blocks of entries of varying sizes (2 or 4)
permuted for each combination of region and recruit-
ment setting (primary or secondary care). The internet-
based computerized randomization system was created and
Key Points
Question Does low-dose theophylline reduce the risk of
exacerbation in patients with chronic obstructive pulmonary
disease (COPD) when added to inhaled corticosteroids?
Findings In this pragmatic randomized clinical trial that included
1567 participants with COPD treated with inhaled corticosteroids,
the addition of low-dose theophylline did not significantly reduce
themean number of exacerbations compared with placebo over a
1-year period (2.24 vs 2.23).
Meaning The findings do not support the use of low-dose
theophylline as adjunctive therapy to inhaled corticosteroids for
prevention of COPD exacerbations.
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administered by the Centre for Healthcare Randomized
Trials, University of Aberdeen.
Intervention
The treatment period was 52 weeks with either theophylline
(Uniphyllin MR), 200 mg-tablets, or visually identical pla-
cebo (Napp Pharmaceuticals). Dosing was based on pharma-
cokinetic modeling incorporating the major determinants of
theophylline plasma concentration and designed to achieve
a steady-state plasma theophylline concentration of 1 to
5mg/L.16Dosingwasdeterminedbytheparticipant’s idealbody
weight (IBW)andsmokingstatus (nonsmokersor smokerswith
IBW≤60kg took 1 theophyllineMR[200mg]or 1placebodaily;
smokerswith IBW>60kg took 1 theophyllineMR [200mg] or
1 placebo twicedaily). Noother changesweremade topartici-
pants’ care, which continued to bemanaged in the usual way
by their primary and secondary care teams.
Outcomes
The primary outcomewas the number of COPD exacerbations
requiringantibiotics,oral corticosteroids,orbothduring the52-
week treatment period as reported by the participant.18 Pa-
tient recallof thisoutcomeishighly reliableoverayear.19Avali-
dationexercisewasconductedat2of the largest recruitingsites.
Atthese2sites,acare/encountersummary(preparedbythegen-
eral practice staff) of a random20%sampleofparticipantswas
requested and compared against participant report of exacer-
bation.Aminimumof2weeksbetweenexacerbationswasnec-
essary to be considered as separate events.18
Outcome data were collected by face-to-face assess-
ments conducted atweek0 (recruitment baseline), 26weeks,
and 52weeks. In addition to exacerbation data, the following
secondaryoutcomeswere collected: participant-reportedun-
scheduled hospital admissions because of severe exacerba-
tions of COPD; unscheduled hospital admissions not related
to COPD; health-related quality-of-life score (EQ-5D-3L
[EuroQol 5Dimension 3Level] scale, −0.59 to 1with 1 indicat-
ing fullhealth,nogenerallyacceptedmeaningfulminimalclini-
cally importantdifference [MCID])20;COPD-relatedhealth sta-
tus (COPDAssessment Test [CAT] scale, 0 to 40with ≤5 being
the norm for healthy nonsmokers and >30 indicating a very
high COPD effect on quality of life, MCID is 2 units)21; modi-
fiedMedical ResearchCouncil (mMRC) dyspnea score (range,
0 [not troubled by breathlessness except on strenuous exer-
cise] to4 [toobreathless to leave thehouseor breathlesswhen
dressing or undressing])22; post bronchodilator spirometry
(FEV1/FVC as percent predicted; for regulatory purposes a
change <3% from baseline is considered as not clinically
important)23,24; adverse reactions or serious adverse events;
episodes of pneumonia; and mortality. Adherence was as-
sessed by pill counting of study drug returns at the 26- and
52-week assessments. In some self-selected recruitment cen-
ters, the Hull Airway Reflux Questionnaire (HARQ) was com-
pletedbyparticipantsat recruitment,6months, and12months
to assess symptoms not elucidated by the CAT ormMRC dys-
pnea scale.25 Health care utilization data were also collected
at recruitment, 6 months, and 12 months for use in a health
economic analysis that will be reported separately.
Participants ceasing studymedicationwereencouraged to
attend the 26- and 52-week assessments to capture outcome
data. For those who did not wish to attend, consent was ob-
tained to send a questionnaire to their general practice about
exacerbations,oralternatively,generalpracticestaff couldsend
anencounter summary fromwhichexacerbationdatawereex-
tracted. The minimum information requested from general
practicewas thenumberofexacerbations in thespecified treat-
ment period, which was often provided without dates of in-
dividual exacerbations.
Sample Size
Data from a previous study indicated that for a trial popula-
tionwith2ormoreexacerbations treatedwithantibiotics, oral
corticosteroids,orbothduring thepreviousyear, themean(SD)
numberof exacerbations in the subsequentyearwouldbe2.22
(1.86).26 An estimated 669 participants were needed in each
trial group to detect a clinically important 15% reduction in
COPDexacerbations (ie, fromameanof 2.22 to 1.89)with90%
power at 5%significance level. There is novalidatedMCID for
COPDexacerbation frequency.24,27The 15%reduction inCOPD
exacerbationswasbasedonconsultationwithprimaryandsec-
ondary care colleagues (general practitioners andpulmonolo-
gists) who considered a 15% reduction to be small but clini-
cally important. A 6% loss to follow-upwas anticipated based
on a systematic review that noted very fewparticipantswith-
drewfromCOPDtheophylline trials.28This inflatedeachstudy
group to 712 participants, giving 1424 in total.
Statistical Methods
All analyses were governed by a statistical analysis plan
(Supplement3).Analysiswas inaccordancewith the intention-
to-treat principle. A per-protocol analysis, excluding nonad-
herent (<70% of doses taken) participants, was performed as
a sensitivity analysis. Adherence was defined as participants
having taken at least 70% of expected doses of study tablets
as determined by pill counting.
Baseline characteristicsweredescribed for both treatment
groups. The primary clinical outcome of number of COPD ex-
acerbationswas compared between randomized groups using
a negative binomial model with an appropriate dispersion pa-
rameter(toadjust forbetween-participantvariability)andlength
of time in the study as an offset. Estimates were adjusted for
baseline covariates known to be related to outcome: age, sex,
pack-yearsof smoking,numberof exacerbations inprevious 12
months, COPD treatment, recruitment setting, and center as a
randomeffect.For thosecovariatesusedinthemodel,anymiss-
ing data were replaced by the value required (and confirmed)
for inclusion in the study (number of exacerbations in previ-
ous year = 2, pack-years = 10, treatment = ICS only). Given the
small amount of missing data for the primary outcome, mul-
tiple imputation was not implemented.
The secondary outcomes of number of exacerbations re-
quiring hospitalization, as well as non-COPD hospital admis-
sions, were analyzed using the samemethods as that used for
the primary outcome. Further exploration of the outcome,
exacerbations requiring hospitalization in a post-hoc analysis,
included inspection of the frequency distribution to ascertain
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if any differences were limited to those with few or many ex-
acerbations.Episodesofpneumonia,all-cause (andrespiratory-
related)mortality,andmMRCscorewereanalyzedusingχ2tests.
Lung function and continuous CAT score were compared be-
tween groups using mixed-effects models. Because there is a
potential for type I error due tomultiple comparisons, second-
ary outcomes should be interpreted as exploratory.
The analysis for the primary outcome was repeated for a
number of prespecified subgroups: age, sex, body mass in-
dex, smoking status at recruitment (former vs current), base-
line treatment for COPD, GOLD stage, exacerbations in 12
monthsprior to recruitment, oral corticosteroiduse at recruit-
ment, and dose of ICS at recruitment. The subgroup analyses
were undertakenby adding a treatment × variable interaction
term to the model using the primary outcome.
AnalyseswereperformedusingStataversion14(StataCorp).
A 5% 2-sided significance level was used throughout.
Results
Participant involvement in the trial is outlined in Figure 1.
Participants were recruited between February 6, 2014,
and August 31, 2016, and final follow-up was completed
August 31, 2017. A total of 1578 participants were random-
ized: 791 to theophylline and 787 to placebo. There were 11
Figure 1. Enrollment, Randomization, and Follow-up of Participants Randomized to Theophylline as Adjunctive Therapy to Inhaled Corticosteroids
vs Placebo for Prevention of COPD Exacerbations
1648 Participants screeneda
70 Excluded (not eligible)
16 Did not have COPD
7 Contraindicated medication
3 Not using ICS
1 Not clinically stable
2 Trial participants
1 On theophylline
1 Theophylline intolerant
1 Pregnant
2 Severe heart disease
8 Did not provide consent
11 Did not meet ≥2 inclusion criteria
10 <2 Exacerbations
7 <10 Pack year smoking
1578 Randomized
791 Randomized to receive
theophylline
788 Received theophylline as
randomized
3 Did not receive theophylline
as randomized
2 Issue with COPD diagnosis
1 Concomitant medication
787 Randomized to receive placebo
779 Received placebo as
randomized
8 Did not receive theophylline
as randomized
4 Concomitant medication
3 Issue with COPD diagnosis
1 Issue with spirometry
591 Included in per-protocol analysis
of primary outcome
589 Included in per-protocol analysis
of primary outcome
788 Included in the theophylline group 779 Included in the placebo group 
16 Excluded (missing primary
outcome data)
15 Excluded (missing primary
outcome data)
203 Actively ceased study medication
3 Never initiated treatment
7 Pill counting adherence <70%b
32 Actively ceased but adherence
≥70% over 52 wk (included in
per-protocol analysis)
6 Never initiated treatment
10 Pill counting adherence <70%b
34 Actively ceased but adherence
≥70% over 52 wk (included in
per-protocol analysis)
193 Actively ceased study medication
772 Included in intention-to-treat
analysis of primary outcome
764 Included in intention-to-treat
analysis of primary outcome
COPD indicates chronic obstructive pulmonary disease.
a Thenumberof potential participants identifiedby screeningof records and sent
invitationswasnot recorded. Theparticipants physically seen for screening
is provided.
bAdherence, as assessed by pill counting, indicated participant nonadherence
because less than 70% of total doses were taken.
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postrandomization exclusions (3 theophylline, 8 placebo), so
1567 participantswere ultimately included: 788 theophylline
and 779placebo. eTable 1 in Supplement 4details the reasons
for postrandomization exclusion. Participantswere recruited
from 121 study sites (88 primary care; 33 secondary care); 941
(60%) participants were identified in primary care. A higher
proportion (26%)ofparticipants thananticipated (6%)didnot
initiate treatment (3 theophylline, 6 placebo) or ceased study
medication (203 theophylline, 193placebo). Theproportionof
participants ceasing studymedicationwas balancedbetween
the theophylline and placebo groups. To counteract this, re-
cruitment continuedwithin the allocated recruitment period
beyond the original target of 1424. The decision to continue
recruitmentwasmadeby the trial steering committee andap-
proved by the funding organization based on aggregated re-
cruitment and study medication cessation data. The investi-
gators, the trial steering committee, and the funder remained
blinded to outcome data throughout the trial.
The baseline characteristics of the participants allocated
to theophylline andplacebowerewell balanced (Table 1). The
mean (SD) age of participants was 68.4 (8.4) years, 54% (843)
weremen, and 31.7% (496)were current smokers. Eighty per-
cent of participants were using triple therapy of ICS, long-
acting-β2-agonists and long-actingmuscarinic antagonists.Al-
thoughmeanFEV1 (51.7%)was indicativeofmoderate tosevere
COPD, 13.5% of participants had very severe COPD and 9.2%
mild. Participants fulfilled the definition of patients with fre-
quent exacerbators27 with a mean (SD) number of self-
reported exacerbations in theprevious year of 3.59 (2.15). CAT
scores indicated that COPD was severely affecting partici-
pants’ lives, (mean [SD], 22.5 [7.7]with65%highorveryhigh).
Primary Outcome
Primary outcome (exacerbation) data were available for 98%
of participants (772 in the theophylline group; 764 in the pla-
cebo group). Therewere 1489person-years of follow-updata.
In total, therewere 3430 exacerbations: 1727 in the theophyl-
line group and 1703 in theplacebo group (meannumber of ex-
acerbations, 2.24 [95%CI, 2.10-2.38] amongparticipants ran-
domized to receive theophylline vs 2.23 [95% CI, 2.09-2.37]
among participants randomized to receive placebo; unad-
justed mean difference, 0.01 [95% CI, −0.19 to 0.21]; unad-
justed incidence rate ratio [IRR], 1.00 [95%CI, 0.92-1.09]; ad-
justed IRR, 0.99 [95% CI, 0.91-1.08]). The incidence of
exacerbations by the month of treatment by GOLD stage (at
baseline) for the2groups ispresented inFigure2.Missingdata
for primary outcomewasminimal (2%), so nomultiple impu-
tation was implemented.
Secondary Outcomes
The analysis of the secondary outcomes is detailed inTable 2.
There were 319 severe COPD exacerbations treated in hospi-
tal (134 in the theophylline group; 185 in the placebo group).
Themean (SD) number of severe COPD exacerbations treated
in hospital was 0.17 (0.49) in the theophylline group vs 0.24
(0.66) in the placebo group (mean difference, −0.07 [95% CI,
−0.13 to −0.01]; unadjusted IRR, 0.72 [95%CI, 0.55-0.95]; ad-
justed IRR, 0.72 [95% CI, 0.55-0.94]; P = .02).
There were no significant differences in non-COPD hos-
pital admissions, episodes of pneumonia, FEV1, CAT score,
mMRC dyspnea score, or mortality (COPD-related and over-
all) between the 2 groups.
Only serious adverse events and adverse reaction data
were collected during the 1-year treatment period. Low-dose
theophylline was not associated with an increase in adverse
reactions or serious adverse events (eTable 4 in Supplement
4). There were no significant differences in the symptom
profiles of serious adverse events between the theophylline
and placebo groups (cardiac, 2.4% vs 3.4%; gastrointestinal,
2.7% vs 1.3%; neurological, 1.4% vs 0.9%) or for adverse
reactions (tachycardia, 1.9% vs 3.5%; nausea, 10.9% vs 7.9%;
insomnia, 10.9% vs 7.9%; headaches, 9.0% vs 7.9%).
For the 2-center validation exercise the general practice
records of 67 participants were examined, and in 53 (79%),
there was complete agreement between participant and gen-
eral practice records.
Per-Protocol Analyses
Theper-protocol analysisexcluded356 (23%)participantswith
less than 70% adherence (181 [23.0%] in the theophylline
group; 175 [22.9%] in the placebo group; P = .80). The rea-
sons for ceasing studymedicationwereequallydistributedbe-
tween the theophylline and placebo groups (eTable 2 in
Supplement 4). Themost common reason for stoppingmedi-
cationwas for gastrointestinal disorders (n=78 [46 in the the-
ophyllinegroup; 32 in theplacebogroup]), 46participantsdis-
continued study medication because they felt no benefit (25
in the theophylline group; 21 in the placebo group), 64 dis-
continued study medication without providing a reason (28
in the theophylline group; 36 in the placebo group), and 29
ceased for social circumstances (15 in the theophylline group;
14 in the placebo group).
For the per-protocol analysis, primary outcome data
were available for 1180 participants (75%) (591 in the the-
ophylline group; 589 in the placebo group), and there were
1146 person-years of follow-up data. There were 2557 exac-
erbations: 1298 in the theophylline group (mean [95% CI],
2.20 [2.04-2.35] exacerbations per year) and 1258 in the pla-
cebo group (mean [95% CI], 2.14 [1.98-2.29] exacerbations
per year); mean difference, 0.06 (95% CI, −0.16 to 0.28);
unadjusted IRR, 1.02 (95% CI, 0.92-1.13); adjusted IRR, 1.00
(95% CI, 0.91-1.10).
Theper-protocol analysisof thesecondaryoutcomesdem-
onstrated that low-dose theophylline reduced the rate of se-
vere COPD exacerbations treated in hospital, mean differ-
ence −0.05 (95% CI, −0.12 to −0.003) and adjusted IRR 0.70
(95%CI, 0.50-0.97), P = .03. Therewere no other statistically
significant differences between the groups (Table 3).
Prespecified Subgroup Analysis
Therewasnoevidence that the treatmenteffectdiffered inany
of the prespecified subgroups (all-interaction P values >.05):
age, sex, body mass index, smoking status at recruitment
(former vs current), baseline COPD treatment, GOLD staging,
exacerbations in 12months prior to recruitment, oral cortico-
steroid use at recruitment, and ICS dose at recruitment.
Research Original Investigation Effect of Theophylline as an Adjunct to Inhaled Corticosteroids on COPD Exacerbations
1552 JAMA October 16, 2018 Volume 320, Number 15 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a Liverpool School of Tropical Medicine User  on 10/16/2018
Table 1. Baseline Characteristics of Participants Randomized to Theophylline and Placebo
Theophylline Group
(n = 788)
Placebo Group
(n = 779)
Age, mean (SD), y 68.3 (8.2) 68.5 (8.6)
Men, No. (%) 425 (53.9) 418 (53.7)
BMI, mean (SD)a 27.1 (6.2) 27.3 (6.0)
Current smoker, No. (%) 247 (31.4) 249 (32.0)
Smoking pack-years, median (IQR) 43.0 (28.5-57.0) 41.0 (27.0-55.0)
COPD treatment, No. (%)
ICS only 13 (1.6) 17 (2.2)
ICS/LABA 136 (17.3) 125 (16.0)
ICS/LAMA 13 (1.6) 10 (1.3)
ICS/LABA/LAMA 625 (79.3) 627 (80.5)
Long-term antibiotics, No./total (%) 51/784 (6.5) 48/771 (6.2)
FEV1 % predicted, No. 785 771
Mean (SD) 51.3 (20.1) 52.2 (19.8)
FEV1 % predicted, GOLD5 stage, No. (%)b
Very severe 116 (14.8) 95 (12.2)
Severe 291 (37.1) 295 (38.4)
Moderate 308 (39.2) 308 (40.0)
Mild 70 (8.9) 73 (9.5)
FEV1/FVC % ratio, No. 783 770
Median (IQR) 47.4 (37.6-59.0) 47.8 (37.5-59.3)
Exacerbations in last 12 moc
Any exacerbation, No. 785 773
Median (IQR) 3 (2-4) 3 (2-4)
Mean (SD) 3.63 (2.21) 3.54 (2.09)
Resulting in hospitalization, No. 784 773
Median (IQR) 0 (0-1) 0 (0-0)
Comorbidities, No./total (%)
Hypertension 317/782 (40.2) 277/772 (35.6)
Treated anxiety or depression ≤last 5 y 222/782 (28.2) 213/772 (27.3)
Asthma 138/782 (17.5) 147/772 (18.9)
Ischemic heart disease 111/781 (14.1) 96/771 (12.3)
Osteoporosis 109/783 (13.8) 90/771 (11.6)
Diabetes mellitus 83/782 (10.5) 93/772 (11.9)
Cerebrovascular event 46/783 (5.8) 58/772 (7.4)
Bronchiectasis 41/782 (5.2) 27/770 (3.5)
mMRC dyspnea score, No. (%) 783 772
0: breathless strenuous exercise 35 (4.5) 50 (6.5)
1: Breathless hurrying 216 (27.6) 224 (28.9)
2: Slower than contemporaries 251 (32.1) 239 (31.0)
3: Stop after 100 m 225 (28.7) 204 (26.5)
4: Breathless leaving house 56 (7.2) 55 (7.2)
COPD assessment test, No. 780 771
Mean (SD) 22.8 (7.5) 22.3 (7.9)
CAT, No. (%)d 780 771
Low effect (0-9) 37 (4.7) 45 (5.8)
Medium effect (10-19) 219 (28.1) 244 (31.7)
High effect (20-29) 361 (46.3) 328 (42.5)
Very high effect (30-40) 163 (20.9) 154 (20.0)
EQ-5D-3L utility, No.e 785 770
Mean (SD) 0.62 (0.28) 0.63 (0.28)
Abbreviations: BMI, bodymass index;
CAT, COPD Assessment Test;
COPD, chronic obstructive pulmonary
disease; EQ-5D, EuroQol 5 dimension
3 level; FEV1, forced expiratory
volume in the first second;
FVC, forced vital capacity;
GOLD, global initiative for chronic
obstructive lung disease; ICS, inhaled
corticosteroids; IQR, interquartile
range; LABA, long-acting β2-agonists;
LAMA, long-acting muscarinic
antagonists.
a BMI is calculated as weight in
kilograms divided by height
in meters squared.
bGOLD5 stage: very severe, FEV1
<30% predicted; severe, FEV1
30%-49% predicted; moderate,
FEV1 50%-79% predicted; mild,
FEV180%predicted.
c Exacerbation is defined as
symptomatic deterioration in COPD
requiring treatment with antibiotics,
oral corticosteroids, or both.
dCAT has a range of 0 to 40 (5 is
the norm for healthy nonsmokers;
>30 indicates a very high COPD
effect on quality of life).
e EQ-5D-3L health outcome
instrument has a scale range of
−0.59 to 1, in which 1 indicates
full health.
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Post Hoc Analyses
The analysis of secondary outcome number of exacerbations
requiring hospital admission showed a significant difference
between theophylline and placebo. On further investigation,
the placebo group had 51more COPD-related hospital admis-
sions than the theophylline group. Inspection of the fre-
quencydistribution (eTable 3 in Supplement 3) indicated that
a small number (n = 10) of participants in the placebo group
with frequent (≥3 /y) COPD-related hospital admissions ac-
counted for 39 of the extra 51 hospital admissions in the pla-
cebo group.
Discussion
This trial showed that among adultswith COPD at high risk of
exacerbation treated with inhaled corticosteroids, the addi-
tionof low-dose theophylline, comparedwithplacebo,didnot
reduce the number COPD exacerbations over a 1-year period.
The primary outcome was COPD exacerbations treated with
oral corticosteroids, antibiotics, or both during 1 year of treat-
ment. Exploratory analyses of 11 prespecified secondary out-
comes indicated that low-dose theophylline had no clinical
effect in 10, including adverse reactions and SAEs.
Preclinical studieshavedemonstrated thatadditionof low-
dose theophylline to corticosteroid therapy has a synergistic
anti-inflammatory effect.29 The few randomized clinical trials
of low-dose theophylline have been small (58-110 partici-
pants), reported contradictory results, and have had major
limitations.30-32Thecurrentpragmatic trial recruited 1578par-
ticipantswith98%ascertainmentof theprimaryoutcome.This
high ascertainment rate was achieved by participants who
ceased study medication attending scheduled study assess-
ments, the request for exacerbationdata fromgeneral practice
staff,ortheinspectionofprimarycarerecords.Thecurrentstudy
attempted to replicate theuseof low-dose theophylline in rou-
tineclinicalpracticewith121geographicallydispersedstudycen-
ters, minimal inclusion criteria, infrequent study assess-
ments, no changes to routine care, usual care settings, anduse
of participant-reported exacerbations. A formal assessment of
thepragmatic featuresof this trial is provided inSupplement5.
The inclusion criterion of at least 2 exacerbations in the
previous year was a pragmatic trade off between clinical rel-
evance, size of eligible population, and sample size. Sample
size requirement was based on a mean (SD) exacerbation rate
of 2.22 (1.86) reported for people with COPD with 2 or more
exacerbations in the previous year26; this was very similar to
the exacerbation rate (2.23-2.24) observed in the current
trial. The exacerbation rate in this trial is somewhat higher
than recent explanatory trials33,34; however, it is consistent
with the recent pragmatic UK Salford Lung Study, which
used an inclusion criterion of at least 1 exacerbation and
reported exacerbation rates of 1.74 to 1.90 per year.35 Previ-
ous low-dose theophylline studies used a single dose for all
participants10,11,30; however, in the current study, theophyl-
line dosing was personalized (determined by IBW and smok-
ing status; designed to achieve plasma theophylline concen-
trations of 1 to 5 mg/L). The use of IBW avoided the potential
for inappropriately high doses of theophylline in overweight
participants. The dosing regimen avoided the need for blood
sampling to measure plasma theophylline concentrations
and the attendant risk of unblinding, and participants in the
low-dose theophylline group did not report an excess of
adverse reactions typical of theophylline toxicity.
In the current trial, low-dose theophylline did reduce
the number of severe COPD exacerbations requiring hospital
admission with most benefit being evident in a small (1%-
2%) subgroup of patients frequently hospitalized with
COPD. Given that adjustments for multiple comparisons
were not performed, it is possible that this finding could be
due to type I error. However, in light of a recent report that
another phosphodiesterase inhibitor (roflumilast) is most
beneficial in people with prior COPD hospitalization for
exacerbation and greater exacerbation frequency,36 this
finding warrants further investigation.
Limitations
This study has several limitations. First, more participants
than anticipated (26%) ceased taking the study drug; how-
ever, this was offset by 10% overrecruitment and a 98%
follow-up rate. When compared with the current trial, most
effectiveness trials of theophylline are relatively short and
Figure 2. Exacerbations for Each TreatmentMonth by Baseline GOLD Stagea for Low-Dose Theophylline
and Placebo Groupsb
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FEV1 indicates forced expiratory
volume in the first second.
a GOLD (global initiative for chronic
obstructive lung disease)6
stage: I mild, FEV180%predicted;
II moderate, FEV1 50%-79%
predicted; III severe, FEV1
30%-49% predicted; IV very
severe, FEV1 <30% predicted.
b Total exacerbations 3420; missing
data points 41.
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exclude people with significant comorbidities.28 This may
explain why the current year-long trial in a population more
representative of the population encountered in clinical prac-
tice witnessed a 26% rate of ceasing study medication, simi-
lar to that reported in a recent year-long low-dose theophyl-
line trial.31 Second, because the study was powered to detect
a 15% reduction in COPD exacerbations, it was unlikely to
detect smaller effects. Although there is no established MCID
for COPD exacerbations, the literature suggests that the
majority of trials consider a reduction in exacerbations of
Table 2. Secondary Outcomes for Participants Randomized to Receive Theophylline and Placebo, Intention-to-Treat Population
Baseline to Week 52
Value (95% CI) P ValueTheophylline Group (n=772) Placebo Group (n=764)
COPD hospital admissions
Total admissions, No. 134 185 Adusted IRR,
0.72 (0.55 to 0.94)a
.02
Mean (SD) per participant 0.17 (0.49) 0.24 (0.66) Mean difference,
−0.07 (−0.13 to −0.01)b
Non-COPD hospital
admissions
Participants, No. 762 755
Total admissions, No. 116 119 Adjusted IRR,
0.99 (0.71 to 1.38)a
Mean (SD) per participant 0.15 (0.56) 0.16 (0.47) Mean difference,
−0.01 (−0.06 to 0.05)b
Week 0 Week 26 Week 52 Week 0 Week 26 Week 52
FEV1 % predicted
Participants, No. 769 553 533 757 539 489 Marginal mean
difference,
−0.57 (−2.51 to 1.36)c
Mean (SD), % 51.2 (20.1) 52.2 (20.5) 51.5 (20.4) 52.3 (19.8) 53.2 (20.9) 52.1 (21.7)
CAT scored
Participants, No. 764 675 633 756 657 615 Marginal mean
difference,
0.01 (−0.65 to 0.68)c
Mean (SD) 22.7 (7.5) 21.3 (8.1) 21.4 (8.2) 22.3 (7.9) 21.1 (8.3) 21.4 (8.6)
mMRC dyspnea score
Participants, No. (%) 767 676 631 757 655 615
0: Breathless strenuous
exercise
35 (4.6) 42 (6.2) 38 (6) 50 (6.6) 51 (7.8) 52 (8.5) 26 wk:
.63e
1: Breathless hurrying 211 (27.5) 209 (30.9) 186 (29.5) 218 (28.8) 189 (28.9) 158 (25.7) 52 wk:
.31e
2: Slower than
contemporaries
248 (32.3) 197 (29.1) 174 (27.6) 235 (31.0) 179 (27.3) 182 (29.6)
3: Stop after 100 m 219 (28.6) 178 (26.3) 178 (28.2) 201 (26.6) 186 (28.4) 167 (27.2)
4: Breathless leaving house 54 (7.0) 50 (7.4) 55 (8.7) 53 (7.0) 50 (7.6) 56 (9.1)
Baseline to Week 52, No./Total (%)
Pneumonia during first 12 mo 14 (1.8) 9 (1.2) Unadjusted OR,
1.55 (0.67 to 3.62)f
.31
All-cause mortality 19 (2.5) 14 (1.8) Unadjusted HR,
1.35 (0.68 to 2.69)g
.40
COPD-related mortality 7 (0.9) 9 (1.2) Unadjusted HR,
0.77 (0.29 to 2.07)g
.61
Adverse reactions 341/709 (48.0) 308/699 (43.9) .12e
Total adverse reactions, No. 883 818
SAEs 103/783 (13.2) 108/770 (14.0) .60e
Total SAEs, No. 141 135
Abbreviations: CAT, COPD Assessment Test, COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in the first second;
HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; SAEs, serious
adverse events.
a Adjusted incidence rate ratio calculated with negative binomial model
adjusting for baseline characteristics of age, sex, pack-years of smoking,
number of exacerbations in previous 12 months, COPD treatment, and
recruitment setting and center as a random effect.
b Indicates unadjustedmean difference in exacerbations per participant.
c Marginal mean difference calculated frommixed-effect models adjusting for
baseline characteristics of age, sex, pack-years of smoking, number of
exacerbations in previous 12 months, COPD treatment, recruitment setting,
and center as a random effect.
d CAT has a range of 0 to 40 (5 is the norm for healthy nonsmokers;
>30 indicates a very high COPD effect on quality of life).
e Comparison between groups calculated using a χ2 test.
f From amixed-effects logistic model.
g From a Cox regressionmodel.
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between 11% and 20% to be clinically important.24,27 The 15%
reduction chosen for this trial was determined after con-
sultation with primary and secondary care colleagues who
considered a 15% reduction to be small but clinically impor-
tant. Third, the primary outcome of exacerbations was
participant-reported rather than documented. Patient recall
of COPD exacerbations has been shown to be highly reliable
over a year,19 and people with COPD do not report all their
exacerbations to health care professionals.3,19,37 Participant
recall of exacerbations in the current study appeared to be
reliable with a 2-center validation exercise demonstrating
79% concordance between participant reporting and general
practice clinical records. Fourth, the definition of exacerba-
tion used in the current study of requiring treatment with
antibiotics and corticosteroids underestimates the frequency
of symptom-defined mild exacerbations that are short lived
and treated with a temporary increase in bronchodilator
use.38 Although these mild exacerbations were not quanti-
fied, there were no differences between groups in quality of
life or health status, suggesting either that low-dose theoph-
ylline had no effect on mild exacerbations or if there was an
effect, it did not affect health status
Table 3. Secondary Outcomes for Participants Randomized to Receive Theophylline and Placebo, Per-Protocol Population
Baseline to Week 52
Value (95% CI) P ValueTheophylline Group (n=591) Placebo Group (n=589)
COPD hospital admissions
Total admissions 92 126 Adjusted IRR,
0.70 (0.50 to 0.97)a
.03
Mean (SD) per participant 0.16 (0.45) 0.21 (0.61) Mean difference,
−0.05 (−0.12 to −0.003)b
Non-COPD hospital
admissions
Participants, No. 587 589
Total admissions 66 85 Adjusted IRR,
0.82 (0.54 to 1.24)a
.35
Mean (SD) per participant 0.11 (0.49) 0.14 (0.45) Mean difference,
−0.03 (−0.08 to 0.02)b
Week 0 Week 26 Week 52 Week 0 Week 26 Week 52
FEV1% predicted
Participants, No. 588 471 455 583 471 432 Marginal mean difference,
−1.33 (−3.47 to 0.80)c
Mean (SD), % 50.7 (20.5) 52.0 (20.8) 51.3 (20.3) 52.8 (20.0) 53.7 (20.9) 52.6 (21.8)
CAT scored
Participants, No. 584 560 534 583 555 527 Marginal mean difference,
0.29 (−0.45 to 1.04)c
Mean (SD) 22.7 (7.5) 21.0 (8.2) 21.0 (8.2) 21.8 (7.9) 20.5 (8.2) 20.9 (8.7)
mMRC dyspnea score
Participants, No. (%) 585 560 534 583 550 527
0: Breathless strenuous
exercise
26 (4.4) 34 (6.1) 32 (6.0) 44 (7.5) 46 (8.3) 47 (8.9) 26 wk:
.43e
1: Breathless hurrying 160 (27.3) 182 (32.5) 167 (31.3) 176 (30.1) 160 (29.0) 149 (28.3) 52 wk:
.34e
2: Slower than
contemporaries
198 (33.8) 161 (28.8) 146 (27.3) 181 (31.0) 155 (28.1) 153 (29.0)
3: Stop after 100 m 157 (26.8) 142 (25.4) 147 (27.5) 149 (25.5) 153 (27.7) 135 (25.6)
4: Breathless leaving house 45 (7.7) 41 (7.3) 43 (8.0) 34 (5.8) 38 (6.9) 43 (8.2)
Baseline to Week 52, No. (%)
Pneumonia during first 12 mo 9 (1.5) 5 (0.8) Unadjusted OR,
1.81 (0.60 to 5.44)f
.29
All-cause mortality 13 (2.2) 9 (1.5) Unadjusted HR,
1.45 (0.62 to 3.38)g
.39
COPD-related mortality 5 (0.8) 5 (0.8) Unadjusted HR,
1.00 (0.29 to 3.46)g
.99
Abbreviations: CAT, COPD Assessment Test, COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in the first second;
HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio.
a Adjusted incidence rate ratio calculated with negative binomial model
adjusting for baseline characteristics of age, sex, pack-years of smoking,
number of exacerbations in previous 12 months, COPD treatment, and
recruitment setting and center as a random effect.
b Indicates unadjustedmean difference in exacerbations per participant.
c Marginal mean difference calculated frommixed-effect models adjusting for
baseline characteristics of age, sex, pack-years of smoking, number of
exacerbations in previous 12 months, COPD treatment, and recruitment
setting and center as a random effect.
d CAT has a range of 0 to 40 (5 is the norm for healthy nonsmokers;
>30 indicates a very high COPD effect on quality of life).
e Comparison between groups calculated using a χ2 test.
f Frommixed-effects logistic model.
g From Cox regressionmodel.
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Conclusions
Among adults with COPD at high risk of exacerbation treated
with inhaled corticosteroids, the addition of low-dose the-
ophylline, compared with placebo, did not reduce the num-
ber COPD exacerbations over a 1-year period. The findings
do not support the use of low-dose theophylline as adjunc-
tive therapy to inhaled corticosteroids for the prevention of
COPD exacerbations.
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Long StrattonMedical Partnership; Ludham and
Stalham Green Surgeries; Mount Farm Surgery;
Mundesley Medical Centre; Nuffield RoadMedical
Centre; Orchard Surgery Dereham; Peninsula
Practice; Portmill Surgery; Rosedale Surgery;
Roundwell Medical Centre; Salisbury House
Surgery; SheringhamMedical Practice; Spinney
Surgery; St Stephens Gate Medical Practice;
St Johns Surgery (Terrington); Staithe Surgery;
The Over Surgery; Trinity and BowthorpeMedical
Practice; Vida Healthcare; Wells Health Centre;
Wellside Surgery; Woodhall FarmMedical Centre;
Woolpit Health Centre; WymondhamMedical
Centre; York Street Medical Practice;North of
England Primary Care Sites: Beacon ViewMedical
Centre; Beaumont Park Medical Group; Belford
Medical Practice; Bellingham Practice; Benfield Park
Medical Centre; Burn BraeMedical Group;
Castlegate and Derwent Surgery; CorbridgeMedical
Group; Elvaston Road Surgery; Fell Cottage Surgery
; GroveMedical Group; Guidepost Medical Group;
Haltwhistle Medical Group; Haydon Bridge and
Allendale Medical Practice; Hetton Group Practice;
Humshaugh andWark Medical Group; Marine
Avenue Surgery; Maryport Health Services; Priory
Medical Group; PrudhoeMedical Group; Seaton
Park Medical Group; Sele Medical Practice; Temple
SowerbyMedical Practice; The Village Surgery;
WaterlooMedical Group; West Farm Surgery; South
West England Primary Care Sites: Barton Surgery;
Bovey Tracey and Chudleigh Practice; Brunel
Medical Practice; Claremont Medical Practice;
ColeridgeMedical Centre; HelstonMedical Centre;
Ide Lane Surgery; Petroc Group Practice; Richmond
House Surgery; Rolle Medical Partnership; Westlake
Surgery;Wessex Primary Care Sites: Friarsgate
Practice; Park and St Francis Surgery; Swanage
Medical Centre.
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